Home » Stocks » APLT

Applied Therapeutics, Inc. (APLT)

Stock Price: $19.73 USD -0.49 (-2.42%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 443.69M
Revenue (ttm) n/a
Net Income (ttm) -87.91M
Shares Out 22.43M
EPS (ttm) -4.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $19.73
Previous Close $20.22
Change ($) -0.49
Change (%) -2.42%
Day's Open 20.04
Day's Range 19.32 - 20.32
Day's Volume 147,188
52-Week Range 15.44 - 55.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validat...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validat...

GlobeNewsWire - 2 months ago

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)

GlobeNewsWire - 2 months ago

Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and imp...

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validat...

Zacks Investment Research - 3 months ago

Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.

24/7 Wall Street - 3 months ago

Applied Therapeutics Inc. (NASDAQ: APLT) shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.

Zacks Investment Research - 3 months ago

Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.

GlobeNewsWire - 3 months ago

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against vali...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against vali...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against vali...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $APLT #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Inves...

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $APLT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Applied Therapeutics, Inc.

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.

Business Wire - 5 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $APLT #fraud--INVESTOR ALERT: Law Offices of Howard G.

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $APLT #APLT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc.

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. ...

PRNewsWire - 5 months ago

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc.

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valid...

Zacks Investment Research - 5 months ago

In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $25.93, marking a +0.5% move from the previous day.

Zacks Investment Research - 5 months ago

Applied Therapeutics Inc. (APLT) closed the most recent trading day at $25.74, moving +1.74% from the previous trading session.

Zacks Investment Research - 6 months ago

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

Zacks Investment Research - 6 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: FREQ, GRBK, KELYA
GlobeNewsWire - 6 months ago

NEW YORK, July 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valid...

Zacks Investment Research - 6 months ago

Is (APLT) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 6 months ago

On July 1, 2020, a fraudulent “short report” was posted.

Zacks Investment Research - 7 months ago

Applied Therapeutics (APLT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 7 months ago

AT-007 pediatric Galactosemia study (ACTION-Galactosemia Kids) initiated

GlobeNewsWire - 7 months ago

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valid...

GlobeNewsWire - 7 months ago

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valida...

GlobeNewsWire - 8 months ago

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against valida...

GlobeNewsWire - 9 months ago

New AT-001 IND opened with FDA for acute lung inflammation and cardiomyopathy in critical COVID-19 patients

Seeking Alpha - 10 months ago

Applied Therapeutics: This Is A Good Entry Point

GlobeNewsWire - 10 months ago

NEW YORK, March 03, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unm...

Zacks Investment Research - 11 months ago

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

Other stocks mentioned: CYH, ENPH, FLGT, TNDM
Zacks Investment Research - 11 months ago

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

Other stocks mentioned: ABEO, EBF, ONTX, PTI
The Motley Fool - 11 months ago

These three clinical-stage biotechs could all double in value before year's end.

Other stocks mentioned: ADAP, KNSA
InvestorPlace - 11 months ago

While the record rally in Tesla stock has garnered all the attention over the past six months, these growth stocks have been just as hot.

Other stocks mentioned: CDLX, EVER, FCEL, HOV, HOVNP
GlobeNewsWire - 11 months ago

NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidat...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidat...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidat...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Applied Therapeutics.

Zacks Investment Research - 1 year ago

Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.

InvestorPlace - 1 year ago

Applied Therapeutics (APLT) news for Wednesday concerning positive results from a clinical trial have APLT stock rocketing higher. The post Applied Therapeutics News: APLT Stock Shoots 32% Hig...

The Motley Fool - 1 year ago

Stellar results from a phase 2 study have investors excited about the biotech's prospects.

Market Watch - 1 year ago

Shares of Applied Therapeutics Inc. APLT, -2.06% jumped 27% in premarket trading on Wednesday after the company said it had positive results from a Phase-2 clinical trial testing AT-007 as a t...

GlobeNewsWire - 1 year ago

AT-007 demonstrated a robust and sustained reduction in galactitol vs placebo; significant plasma galactitol reduction of ~50% (p

The Motley Fool - 1 year ago

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APRE, BNTX, GKOS, INMD, KRTX, NXTC, PLMR, RAPT, TPTX
GlobeNewsWire - 1 year ago

NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board,...

About APLT

Applied Therapeutics, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 f... [Read more...]

Industry
Biotechnology
IPO Date
May 14, 2019
CEO
Dr. Shoshana Shendelman Ph.D.
Employees
22
Stock Exchange
NASDAQ
Ticker Symbol
APLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for APLT stock is "Strong Buy." The 12-month stock price forecast is 53.00, which is an increase of 168.63% from the latest price.

Price Target
$53.00
(168.63% upside)
Analyst Consensus: Strong Buy